This review explores the different aspects of constitutional factors in early life that modulate toxicokinetics and
toxicodynamics of low-dose mercury resulting from acute ethylmercury (etHg) exposure in Thimerosal-containing vaccines
Major databases were searched for human and experimental studies that addressed issues related to early life exposure to
TCV. It can be concluded that: a) mercury load in fetuses, neonates, and infants resulting from TCVs remains in blood of
neonates and infants at sufficient concentration and for enough time to penetrate the brain and to exert a neurologic impact
and a probable influence on neurodevelopment of susceptible infants; b) etHg metabolism related to neurodevelopmental
delays has been demonstrated experimentally and observed in population studies; c) unlike chronic Hg exposure during
pregnancy, neurodevelopmental effects caused by acute (repeated/cumulative) early life exposure to TCV-etHg remain
unrecognized; and d) the uncertainty surrounding low-dose toxicity of etHg is challenging but recent evidence indicates
that avoiding cumulative insults by alkyl-mercury forms (which include Thimerosal) is warranted. It is important to a)
maintain trust in vaccines while reinforcing current public health policies to abate mercury exposure in infancy; b) generally
support WHO policies that recommend vaccination to prevent and control existing and impending infectious diseases;
and c) not confuse the ’need’ to use a specific ‘product’ (TCV) by accepting as ’innocuous’ (or without consequences) the
presence of a proven ‘toxic alkyl-mercury’ (etHg) at levels that have not been proven to be toxicologically safe.
Keywords: Thimerosal, ethylmercury, methylmercury, hair, blood, stools, vaccines, newborns, neurodevelopment.
Rights & PermissionsPrintExport